If it can be proven that Apabetalone reduces 30 day hospital reaadmissions for decompensated heart failure would be huge. Medicare does not pay for these re-admits and the cost falls squarely on the hospital. Places incredible pressure on administration and providers, especially on institutions whom demographics are primarily cater to lower income class and uneducated patients.